{"id":"https://openalex.org/W2047831782","doi":"https://doi.org/10.1016/s0924-977x(00)80384-3","title":"Differential actions of the new antipsychotic agents","display_name":"Differential actions of the new antipsychotic agents","publication_year":2000,"publication_date":"2000-09-01","ids":{"openalex":"https://openalex.org/W2047831782","doi":"https://doi.org/10.1016/s0924-977x(00)80384-3","mag":"2047831782"},"language":"en","primary_location":{"id":"doi:10.1016/s0924-977x(00)80384-3","doi":"https://doi.org/10.1016/s0924-977x(00)80384-3","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(00)80384-3","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"N.A. Moore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"N.A. Moore","raw_affiliation_strings":["Lilly Research Centre, Eli Lilly & Co., Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Centre, Eli Lilly & Co., Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110261041","display_name":"Frank P. Bymaster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F.P. Bymaster","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, IN 46285, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, IN 46285, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025014357","display_name":"P. Tran","orcid":"https://orcid.org/0009-0004-2192-8032","observed_orcids":["https://orcid.org/0009-0004-2192-8032"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Tran","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, IN 46285, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, IN 46285, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110607987","display_name":"Alan F. Breier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Breier","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, IN 46285, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, IN 46285, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109214489","display_name":"Gary D. Tollefson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G.D. Tollefson","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, IN 46285, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, IN 46285, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.17516447,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":null,"first_page":"321","last_page":"322"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.6723999977111816,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.6723999977111816,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.16279999911785126,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.14790000021457672,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.906000018119812},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.9309999942779541},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":1.0},{"id":"https://openalex.org/keywords/nmda-receptor","display_name":"NMDA receptor","score":0.699999988079071},{"id":"https://openalex.org/keywords/ampa-receptors","display_name":"AMPA receptors","score":0.8569999933242798},{"id":"https://openalex.org/keywords/glutamatergic-neurotransmission","display_name":"glutamatergic neurotransmission","score":0.9010000228881836},{"id":"https://openalex.org/keywords/medial-prefrontal-cortex","display_name":"medial prefrontal cortex","score":0.921999990940094},{"id":"https://openalex.org/keywords/pyramidal-neurons","display_name":"pyramidal neurons","score":0.9440000057220459},{"id":"https://openalex.org/keywords/receptor-desensitization","display_name":"receptor desensitization","score":0.9300000071525574},{"id":"https://openalex.org/keywords/resting-membrane-potential","display_name":"resting membrane potential","score":0.6679999828338623},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8510000109672546},{"id":"https://openalex.org/keywords/typical-antipsychotics","display_name":"typical antipsychotics","score":0.8610000014305115}],"concepts":[{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.9023287296295166},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.7916457653045654},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.7551157474517822},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.7003829479217529},{"id":"https://openalex.org/C2781195155","wikidata":"https://www.wikidata.org/wiki/Q18680","display_name":"Prefrontal cortex","level":3,"score":0.6377953886985779},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6101000905036926},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5044504404067993},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4732570946216583},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.42124420404434204},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40392640233039856},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.35029876232147217},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33987662196159363},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.2435561716556549},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.23083338141441345},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.22593143582344055},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.16406592726707458},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.09994259476661682},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s0924-977x(00)80384-3","doi":"https://doi.org/10.1016/s0924-977x(00)80384-3","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(00)80384-3","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5099999904632568,"id":"https://metadata.un.org/sdg/5","display_name":"Gender equality"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":3,"referenced_works":["https://openalex.org/W1985517071","https://openalex.org/W2004477107","https://openalex.org/W2022769813"],"related_works":["https://openalex.org/W2050180518","https://openalex.org/W1975368696","https://openalex.org/W2111521524","https://openalex.org/W2133757259","https://openalex.org/W1938004598","https://openalex.org/W2039594565","https://openalex.org/W2092895227","https://openalex.org/W2052441880","https://openalex.org/W1994584257","https://openalex.org/W2118362234"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}